|Bid||186.78 x 3000|
|Ask||187.19 x 1000|
|Day's range||186.22 - 201.80|
|52-week range||48.21 - 331.68|
|Beta (5Y monthly)||1.55|
|PE ratio (TTM)||N/A|
|Earnings date||09 Aug 2021 - 13 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||258.00|
Novavax (NVAX) will be able to pursue emergency use authorization following new information that shows its COVID-19 vaccine is 90% effective.
Dynavax Technologies (NASDAQ: DVAX) stock was down 6.3% as of 11:26 a.m. EDT, while shares of Novavax (NASDAQ: NVAX) and Vaxart (NASDAQ: VXRT) were falling 7.8% and 10.6%, respectively. The declines for the biotech stocks appear to merely be run-of-the-mill volatility on a day when the overall stock market was down. Sales of its Heplisav-B hepatitis B vaccine were negatively impacted by the COVID-19 pandemic.
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, shows an overall efficacy of 90% in the phase III PREVENT-19 study in the United States and Mexico.